This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.
Becton Dickinson (BDX) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 6.83% and 4.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stocks Earnings on Aug 4: BDX, ABMD, AMN & DOCS
by Debanjana Dey
The Medical Device companies' Q2 results are likely to reflect strength in customer demand. Let's see how BDX, ABMD, AMN and DOCS are placed ahead of their earnings releases.
Zacks Industry Outlook Highlights Becton, Dickinson and Company, Patterson Companies and SmileDirectClub
by Zacks Equity Research
Becton, Dickinson and Company, Patterson Companies and SmileDirectClub are part of Zacks Industry Outlook article.
BD (BDX) Gears Up for Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Interventional segment is expected to have driven up Q3 sales.
3 Dental Supplies Stocks to Buy Amid Industry Headwinds
by Zacks Equity Research
Here we discuss three stocks from the Dental Supplies industry that are likely to create wealth for investors - BDX, PDCO and SDC.
Analysts Estimate Becton Dickinson (BDX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BDX or ALGN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BDX vs. ALGN: Which Stock Is the Better Value Option?
Earnings Season Scorecard and Fresh Analyst Research Reports for Chevron, Adobe & AMD
by Sheraz Mian
Today's Research Daily features update on the Q2 earnings season and new research reports on Chevron (CVX), Adobe (ADBE), AMD (AMD) and 16 other stocks.
3 Reasons Why BD (BDX) is a Great Pick For Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to a few regulatory approvals and strategic deals.
3 Reasons to Add Accuray (ARAY) Stock to Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about Accuray (ARAY) owing to strong demand for its products.
Cardinal Health's (CAH) New Buyout to Boost Medication Adherence
by Zacks Equity Research
Cardinal Health's (CAH) latest acquisition is expected to significantly improve patients' health outcomes with improved medication adherence and increased satisfaction.
BDX vs. ALGN: Which Stock Is the Better Value Option?
by Zacks Equity Research
BDX vs. ALGN: Which Stock Is the Better Value Option?
BD's (BDX) New Combination Test to Boost Patient Outcome
by Zacks Equity Research
BD's (BDX) latest combination test is expected to speed up the detection of the infection-causing viruses, thereby accelerating the implementation of the appropriate treatment plan.
BD (BDX) Integrates Innovative Solution to Boost Patient Care
by Zacks Equity Research
BD's (BDX) announcement of the implementation of BD HealthSight brings together timely monitoring to support the early detection of emerging healthcare infections, thereby improving patient care.
BD's (BDX) Latest Collaboration to Enhance Patient Care
by Zacks Equity Research
BD's (BDX) new partnership is expected to increase efficiency for new clinical trials, generate evidence, support new claims for its products and streamline medical device regulatory submissions.
Why Is Dentsply (XRAY) Up 6.2% Since Last Earnings Report?
by Zacks Equity Research
Dentsply (XRAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BD's (BDX) New Tie-Up to Develop Detection Kit for Monkeypox
by Zacks Equity Research
BD's (BDX) partnership with CerTest is expected to aid in advancing the understanding of the monkeypox virus' global spread.
BD (BDX) to Expand Base in Pharmacy Automation With New Buyout
by Zacks Equity Research
BD's (BDX) buyout of Parata Systems is expected to advance its 2025 strategy to accelerate innovation in smart, connected care and enabling new care settings.
BD's (BDX) Latest Product to Transform Research Outcome
by Zacks Equity Research
BD's (BDX) latest cell sorting technology is expected to speed up the process of cell sorting as well as provide answers to previously unthinkable questions.
New Strong Sell Stocks for May 27th
by Zacks Equity Research
ACER, BBWI, and BDX have been added to the Zacks Rank #5 (Strong Sell) List on May 27, 2022.
New Strong Sell Stocks for May 25th
by Zacks Equity Research
ALGN, AUD, and BDX have been added to the Zacks Rank #5 (Strong Sell) List on May 25, 2022.
BD (BDX) Introduces New Molecular Diagnostic Platform in US
by Zacks Equity Research
BD's (BDX) new fully-automated, high-throughput infectious disease molecular diagnostics platform in the United States to aid lab technicians in prioritizing higher value work.
BD (BDX) Extends Partnership to Boost Diagnostic Blood Collection
by Zacks Equity Research
BD (BDX) expands strategic partnership with Babson Diagnostics that will enable less invasive blood sample collection easier and patient-centric.
New Strong Sell Stocks for May 13th
by Zacks Equity Research
DDD, AMRN, and BDX have been added to the Zacks Rank #5 (Strong Sell) List on May 13, 2022.
Company News for May 6, 2022
by Zacks Equity Research
Companies In The News Are: SHOP, WRK, BDX, ALB.